Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:CDTX News 14 November 2025 - 9 January 2026

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck shares rose 0.4% to $111.41 Friday after a report said it is in talks to buy Revolution Medicines for $28–32 billion. Revolution shares jumped 16% in extended trading. Merck just completed a $221.50-per-share tender offer for Cidara Therapeutics and said the deal will raise 2026 R&D expense by $9 billion. Analysts warned U.S. vaccine policy changes could cut Merck revenue by $2 billion annually.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck shares rose 1.2% to $106.45 Friday after Nasdaq set Jan. 6 as the expiration for its $9.2 billion cash tender offer for Cidara Therapeutics. Cidara shares will be halted after Jan. 6 and suspended Jan. 8 if the merger closes as planned. Merck’s move snapped a three-day losing streak, leaving the stock just below its 52-week high. About 10 million shares traded, below the 50-day average.
3 January 2026
···
Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

As of 2:34 a.m. ET in New York on Saturday, December 27, 2025, U.S. stock markets are closed for the weekend.Merck & Co., Inc. (NYSE: MRK) was last quoted around $106.78, up about 0.33% versus its prior close, based on the latest available pricing feed. With year-end trading under way and liquidity often thinner around the holidays, Merck is heading into the next session with an unusually packed headline stack: policy-driven drug pricing news, FDA review acceleration for two experimental therapies, and portfolio diversification via M&A—all against the backdrop of investors constantly re-litigating the same big question: how Merck replaces
27 December 2025
···
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Cidara Therapeutics, Inc. (NASDAQ: CDTX) is at the center of Wall Street’s attention today after Merck & Co., Inc. (NYSE: MRK) agreed to acquire the San Diego–based biotech in a cash deal valued at approximately $9.2 billion, sending CDTX shares more than 100% higher in a single session. Reuters+1 Below is a detailed look at today’s news (14 November 2025), the science behind Cidara’s lead flu-prevention asset CD388, the stock market reaction, and the wave of shareholder-law-firm investigations that emerged within hours of the announcement. Merck to Acquire Cidara for $221.50 Per Share in Cash Merck and Cidara announced this
14 November 2025
··

Stock Market Today

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

XRP price today slips near $1.42 as thin weekend liquidity keeps traders on edge

7 February 2026
XRP fell about 5% Saturday to $1.42, extending a 22% weekly drop as thin liquidity and macro jitters drove sharp swings. Bitcoin rebounded above $70,000 after a brief plunge, while ether surged 12%. Ripple outlined plans for an “Institutional DeFi” roadmap, including a new lending protocol and permissioned DEX. The Federal Reserve held rates steady last week, with officials signaling caution on inflation.
Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
Go toTop